Business Context and Reporting Period
This Form 6-K filing by Immuron Ltd (Immuron) is dated July 3, 2017. The report serves to disclose two specific corporate events published on the Australian Securities Exchange (ASX) on the same date: a Change of Director's Interest Notice (Appendix 3Y) and a press release regarding pre-clinical results for the company's drug candidate IMM-529 in the treatment of Clostridium difficile Infection (CDI).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of specific events and does not contain a financial statement or performance summary.
Material Changes
- Director's Interest: A change in a director's interest was reported via an Appendix 3Y notice.
- Scientific Development: Pre-clinical results for IMM-529 in CDI were published in the journal Scientific Reports.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that future statements may be subject to uncertainties and risks detailed in the company's Form F-1 and other SEC reports. The document explicitly states it is not an offer to sell securities in the United States. No specific financial guidance or management commentary on future financial performance is provided in this text.
Investor Verification Checklist
- Verify the specific details of the Director's interest change in the attached Appendix 3Y (Exhibit 99.1).
- Review the full pre-clinical data for IMM-529 in CDI as detailed in the attached Press Release (Exhibit 99.2) and the publication in Scientific Reports.
- Consult the company's most recent Form 20-F or Form 6-K for actual financial metrics, as this filing contains none.